Tarperprumig clinical trials
Also written ALXN1820.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses tarperprumig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tarperprumig.
- Oct 2027Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisPhase 2 · Alexion Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses tarperprumig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisActive, not recruitingPhase 2Alexion Pharmaceuticals, Inc.NCT07160608Written as Tarperprumig
- Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell DiseaseTerminatedPhase 2Alexion Pharmaceuticals, Inc.NCT05565092Written as ALXN1820
- Study of ALXN1820 in Healthy Adult ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04631562Written as ALXN1820 SC
Codes
What other systems call tarperprumig · ClinicalTrials.gg INT015433
- UNII (FDA) 799C2S3RNCTARPERPRUMIGOne source FDA
- NCI Thesaurus C207000TarperprumigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 799C2S3RNC | TARPERPRUMIG | One source FDA |
| NCI Thesaurus | C207000 | Tarperprumig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.